Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years

Author： Iversen P.   Tyrrell C.J.   Kaisary A.V.   Anderson J.B.   Baert L.   Tammela T.   Chamberlain M.   Carroll K.   Gotting-Smith K.   Blackledge G.R.P.  

Publisher： Elsevier

ISSN： 0090-4295

Source： Urology, Vol.51, Iss.3, 1998-03, pp. : 389-396

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Randomised Comparison of Bicalutamide ('Casodex') 150 mg versus Placebo as Immediate Therapy Either Alone or as Adjuvant to Standard Care for Early Non-Metastatic Prostate Cancer - First Report from the Scandinavian Prostatic Cancer Group Study No. 6

By Iversen P.   Tammela T.L.J.   Vaage S.   Lukkarinen O.   Lodding P.   Bull-Njaa T.   Viitanen J.   Hoisaeter P.   Lundmo P.   Rasmussen F.   Johansson J.-E.   Persson B.-E.   Carroll K.   Scandinavian Prostatic Cancer Group SPCG  

European Urology, Vol. 42, Iss. 3, 2002-09 ,pp. : 204-211

Elsevier

Access to resources Recommend Favorite

Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression

By Wirth M.   Tyrrell C.   Wallace M.   Delaere K.P.   Sanchez-Chapado M.   Ramon J.   Hetherington J.   Pina F.   Heynes C.F.   Borchers T.M.   Morris T.   Stone A.  

Urology, Vol. 58, Iss. 2, 2001-08 ,pp. : 146-150

Elsevier

Access to resources Recommend Favorite

Immediate Therapy in Early Prostate Cancer: Results from the Bicalutamide ('Casodex') EPC Programme

By Wirth M.   Iversen P.   McLeod D.   See W.  

European Urology Supplements, Vol. 1, Iss. 7, 2002-10 ,pp. : 20-25

Elsevier

Access to resources Recommend Favorite

Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up

By Oh W.K.   Manola J.   Bittmann L.   Brufsky A.   Kaplan I.D.   Smith M.R.   Kaufman D.S.   Kantoff P.W.  

Urology, Vol. 62, Iss. 1, 2003-07 ,pp. : 99-104

Elsevier

Access to resources Recommend Favorite

Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer

By Stephenson A.J.   Aprikian A.G.   Souhami L.   Behlouli H.   Jacobson A.I.   Begin L.R.   Tanguay S.  

Urology, Vol. 59, Iss. 5, 2002-05 ,pp. : 652-656

Elsevier

Access to resources Recommend Favorite